Candida Bloodstream Infection, a Dire Complication in Hospitalized COVID-19 Patients: Three Cases from a Single Center in Northern Israel

Isr Med Assoc J. 2021 Oct;23(10):615-617.

Abstract

Background: Patients with severe coronavirus disease-2019 (COVID-19) are susceptible to superimposed infections.

Objectives: To describe COVID-19 patients who presented with complications due to Candida bloodstream co-infection (candidemia) and their outcome in a single center in northern Israel (Emek Medical Center) during the second outbreak of COVID-19 in Israel (15 June 2020 to 20 September 2020).

Methods: A retrospective study of COVID-19 patients presenting with candidemia was conducted, including clinical and laboratory data. The incidence of candidemia among hospitalized COVID-19 patients was compared to a historical cohort of non-COVID-19 controls.

Results: Three COVID-19 patients complicated with candidemia were documented. All three patients died shortly after the detection of candidemia. Three different Candida sp. were isolated from the blood cultures: C. albicans, C. parapsilosis, and C. glabrata. The incidence of candidemia among COVID-19 patients was 0.679 episodes per 1000 hospital days.

Conclusions: Our small sample suggests a much higher incidence of candidemia among COVID-19 patients compared to a historical cohort of non-COVID-19 controls. All clinicians treating COVID-19 patients in GICU should be aware of this complication.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antifungal Agents / administration & dosage
  • COVID-19* / complications
  • COVID-19* / physiopathology
  • COVID-19* / therapy
  • Candida / isolation & purification*
  • Candidemia* / complications
  • Candidemia* / diagnosis
  • Candidemia* / drug therapy
  • Caspofungin / administration & dosage*
  • Catheterization, Central Venous / methods
  • Coinfection* / diagnosis
  • Coinfection* / microbiology
  • Coinfection* / therapy
  • Critical Care / methods
  • Cross Infection* / diagnosis
  • Cross Infection* / microbiology
  • Cross Infection* / therapy
  • Fatal Outcome
  • Female
  • Hospitalization / statistics & numerical data
  • Humans
  • Male
  • Respiration, Artificial / methods
  • SARS-CoV-2 / isolation & purification
  • Severity of Illness Index

Substances

  • Antifungal Agents
  • Caspofungin